Showing 3101-3110 of 5646 results for "".
- LumiThera Completes Acquisition of Diopsyshttps://modernod.com/news/lumithera-completes-acquisition-of-diopsys/2480675/LumiThera announced the completion of its acquisition of Diopsys, a provider of modern visual electrophysiology medical devices. Diopsys is now a wholly owned subsidiary of LumiThera. Financial terms the transaction were not disclosed. EyewireTV's covereage of the acq
- Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successorhttps://modernod.com/news/spark-therapeutics-announces-departure-of-ceo-and-founder-jeff-marrazzo-coo-ron-philip-named-as-successor/2480664/Spark Therapeutics, a member of the Roche Group, announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey D. Marrazzo as chief executive officer. Mr. Marrazzo, who co-founded the company in 2013, will step down on April 1. “When I thin
- Nicox Announces Vyzulta Now Commercialized in 7 Territories and Approved in Further 9 Countrieshttps://modernod.com/news/nicox-announces-vyzulta-now-commercialized-in-7-territories-and-approved-in-further-9-countries/2480660/Nicox provided an update on the approvals and launches of Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%, exclusively licensed worldwide by Nicox to Bausch + Lomb. “Vyzulta is the first product based on our nitric oxide-donating research platform which has bee
- Oyster Point Pharma Announces Tyrvaya Nasal Spray Now Covered by Express Scriptshttps://modernod.com/news/oyster-point-pharma-announces-tyrvaya-nasal-spray-now-covered-by-express-scripts/2480656/Oyster Point Pharma announced Tyrvaya Nasal Spray’s placement on the Express Scripts National Preferred, Basic, and High Performance Formularies, which collectively covers an estimated 26 million people, effective February 19, 2022. Tyrvaya is the first and only na
- Study Shows Significant Impact of Novel Omega-3 and Omega-6 Supplement for People with Severe Dry Eye Diseasehttps://modernod.com/news/study-shows-significant-impact-of-novel-omega-3-and-omega-6-supplement-for-people-with-severe-dry-eye-disease/2480627/A newly-published study conducted by the
- Maintaining Transparency: Study to Focus on Causes of Cataractshttps://modernod.com/news/maintaining-transparency-study-to-focus-on-causes-of-cataracts/2480616/Researchers at the University of Arizona College of Medicine – Tucson are leading a study to identify the biological mechanisms that cause cataracts in the hopes that new, nonsurgical treatments may be developed. Nicholas Delame
- Tarsus Appoints José Trevejo, MD, PhD, Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-jose-trevejo-md-phd-chief-medical-officer/2480613/Tarsus Pharmaceuticals announced the appointment of José Trevejo, MD, PhD, as Chief Medical Officer. Dr. Trevejo brings over 20 years of experience advancing the clinical development of novel therapeutics for serious diseases. Dr. Trevejo’s leadership will be highly valued
- MeiraGTx Receives Clinical Development Milestone Payment from Janssenhttps://modernod.com/news/meiragtx-receives-clinical-development-milestone-payment-from-janssen/2480599/MeiraGTx Holdings announced that it has received a $30 million payment from Johnson & Johnson's Janssen Pharmaceuticals for a clinical milestone in the phase 3 Lumeos trial of botaretigene sparoparvovec (AAV-RPGR), an investigational gene therapy for the treatment of X-linked retinit
- Pixium Vision Announces the Publication of Peer-Reviewed Clinical Data Demonstrating the Clinical Benefit of the Prima System in Dry AMD Patientshttps://modernod.com/news/pixium-vision-announces-the-publication-of-peer-reviewed-clinical-data-demonstrating-the-clinical-benefit-of-the-prima-system-in-dry-amd-patients/2480597/Pixium Vision SA announced the publication of a paper in Nature Communications outlining further data with its Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision in atrophi
- Nanoscope Therapeutics Announces FDA Clearance of IND for MCO-010 Gene Therapy in Stargardt Macular Degeneration Patientshttps://modernod.com/news/nanoscope-therapeutics-announces-fda-clearance-of-ind-for-mco-010-gene-therapy-in-stargardt-macular-degeneration-patients/2480594/Nanoscope Therapeutics announced it received IND clearance from the FDA to begin a phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy to restore vision in Stargardt patients. “This is another important milestone for Nanoscop